RAB18: A Potential Drug Target and biomarker for the RAS Oncogene Family

Target Name: RAB18

NCBI ID: G22931

RAB18

RAB18: A Potential Drug Target and biomarker for the RAS Oncogene Family

The RAS (Ras-associated protein) gene is a key regulator of cell growth, differentiation, and survival, and is implicated in numerous diseases, including cancer. The RAS oncogene family is a subgroup of the RAS gene that has been implicated in the development and progression of many diseases, including cancer. RAB18 is a member of the RAS oncogene family and is a potential drug target and biomarker for this family.

The RAS oncogene family consists of four genes: RAB1, RAB2, RAB3, and RAB18. These genes encode for proteins that are involved in the regulation of cell growth, differentiation, and survival, as well as in the development and progression of diseases. The RAB1 gene encodes for a protein that is involved in the regulation of cell adhesion and in the development of cancer. The RAB2 gene encodes for a protein that is involved in the regulation of cell survival and in the development of cancer. The RAB3 gene encodes for a protein that is involved in the regulation of cell growth and in the development of cancer. The RAB18 gene encodes for a protein that is similar to the RAB1 protein but with some differences in its sequence and structure.

RAB18 is a potential drug target for the RAS oncogene family because it has been shown to be involved in the development and progression of many diseases, including cancer. For example, studies have shown that high levels of RAB18 are associated with poor prognosis in individuals with pancreatic ductal adenocarcinoma, a type of cancer that is characterized by the formation of malignant cells in the pancreatic ducts. Additionally, RAB18 has been shown to be involved in the development of colorectal cancer, and high levels of RAB18 have been shown to be associated with the development of this disease.

In addition to its potential as a drug target, RAB18 has also been shown to be a potential biomarker for the RAS oncogene family. The expression of RAB18 has been shown to be regulated by various factors, including growth factors, such asGFP-1, and inhibitors, such as PDGF-BB. Additionally, RAB18 has been shown to be involved in the regulation of cell survival, and its levels have been shown to be associated with the survival of cancer cells.

Another potential mechanism by which RAB18 may be involved in the development and progression of diseases is through its role in cell signaling pathways. For example, RAB18 has been shown to be involved in the regulation of the PI3K/Akt signaling pathway, a pathway that is involved in the regulation of cell survival and growth. Additionally, RAB18 has been shown to be involved in the regulation of the TGF-β signaling pathway, a pathway that is involved in the regulation of cell growth and differentiation.

Conclusion

In conclusion, RAB18 is a member of the RAS oncogene family and has been shown to be involved in the development and progression of many diseases, including cancer. Its potential as a drug target and biomarker makes it an attractive target for research into the treatment of these diseases. Further studies are needed to fully understand the role of RAB18 in the RAS oncogene family and its potential as a drug and biomarker.

Protein Name: RAB18, Member RAS Oncogene Family

Functions: The small GTPases Rab are key regulators of intracellular membrane trafficking, from the formation of transport vesicles to their fusion with membranes (PubMed:24891604, PubMed:30970241). Rabs cycle between an inactive GDP-bound form and an active GTP-bound form that is able to recruit to membranes different sets of downstream effectors directly responsible for vesicle formation, movement, tethering and fusion (PubMed:24891604, PubMed:30970241). Required for the localization of ZFYVE1 to lipid droplets and for its function in mediating the formation of endoplasmic reticulum-lipid droplets (ER-LD) contacts (PubMed:30970241). Also required for maintaining endoplasmic reticulum structure (PubMed:24891604). Plays a role in apical endocytosis/recycling (By similarity). Plays a key role in eye and brain development and neurodegeneration (PubMed:21473985)

The "RAB18 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RAB18 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets